Gastrointestinal tolerability of NSAIDs in elderly patients: A pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs

Current Medical Research and Opinion

Volumn 27, Issue 7, 2011, Pages 1359-1366

  Mallen, Sharon R ^a   Essex, Margaret N ^a   Zhang, Richard ^a  

^a PFIZER INC   (United States)

Author keywords

COX 2 selective NSAIDs; Elderly; Gastrointestinal tolerability; NSAIDs; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; AGED; ANKYLOSING SPONDYLITIS; ARTHRITIS; COMPARATIVE STUDY; CONSTIPATION; DIARRHEA; DRUG TOLERABILITY; DYSPEPSIA; ELDERLY CARE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; NAUSEA; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; INCIDENCE; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SUBSTRATE SPECIFICITY; SULFONAMIDES;

EID: 79958797811     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.581274     Document Type: Review

References (20)

1. Elders MJ. The increasing impact of arthritis on public health. J Rheumatol Suppl 2000;60:6-8.
2. Buckwalter JA, Saltzman C, Brown T. The impact of osteoarthritis: implications for research. Clin Orthop Relat Res 2004;427(Suppl):S6-15.
3. Pilotto A, Franceschi M, Leandro G, et al.; for the Geriatric Gastroenterology Study Group (Societè Italiana Gerontologie Geriatria). NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies. Drugs Aging 2003;20:701-10. (Pubitemid 36920513)
4. Larkai EN, Smith JL, Lidsky MD, et al. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 1989;11:158-62. (Pubitemid 19104436)
5. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998;104:23-9S.
6. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999;56:18-24. (Pubitemid 29183022)
7. Wolfe F, Kong SX, Watson DJ. Gastrointestinal symptoms and health related quality of life in patients with arthritis. J Rheumatol 2000;27:1373-8. (Pubitemid 30354030)
8. Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision- making? Soc Sci Med 1992;34:507-13.
9. Walker AM, Chan KW, Yood RA. Patterns of interchange in the dispensing of non-steroidal anti-inflammatory drugs. J Clin Epidemiol 1992;45:187-95.
10. Scholes D, Stergachis A, Penna PM, et al. Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritis. J Rheumatol 1995;22:708-12.
11. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-11. (Pubitemid 30008893)
12. Bensen WG, Zhao SZ, Burke TA, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000;27:1876-83.
13. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
14. Goldstein JL, Eisen GM, Burke TA, et al. Dyspepsia tolerability from the patient's perspective: a comparison of celecoxib with diclofenac. Aliment Pharmacol Ther 2002;16:819-27. (Pubitemid 34407532)
15. McKenna F, Arguelles L, Burke T, et al. Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis. Clin Exp Rheumatol 2002;20:35-43. (Pubitemid 34213730)
16. Moore RA, Derry S, Makinson GT, et al. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005;7:R644-65.
17. Singh G, Fort JG, Goldstein JL, et al.; for the SUCCESS-I Investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006;119:255-66. (Pubitemid 43255067)
18. Niculescu L, Li C, Huang J, et al. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs. Curr Med Res Opin 2009;25:729-40.
19. Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008;12:1-278.
20. Goupille P, Logeart I, Combe B. Naturalistic survey on nonsteroidal antiinflammatory treatment in patients with musculoskeletal pain. Joint Bone Spine 2003;70:219-25 (Pubitemid 36753474)